Literature DB >> 19444462

Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy.

Christof Schaefer1, Reinhard Meister, Corinna Weber-Schoendorfer.   

Abstract

OBJECTIVE: Apart from thalidomide, retinoids like isotretinoin are the strongest teratogens in humans known today. The overall risk of birth defects is estimated as up to 30% after exposure during embryogenesis. In spite of well established pregnancy prevention programs, pregnancies still occur during isotretinoin therapy in many countries including Germany. A detailed investigation of the incidence and outcome of these pregnancies would fill an important gap.
METHODOLOGY: The Berlin Institute for Clinical Teratology documents prospectively the course of drug-exposed pregnancies when contacted for individual drug risk assessment. Datasets of isotretinoin exposed pregnancies recorded between 1993 and 2008 were evaluated as to the outcome of pregnancy.
RESULTS: A total of 108 pregnancies exposed to systemic isotretinoin (median dosage 20 mg/day) during the contraindicated period were registered. 76% (69/91) of the pregnancies with known outcome were electively terminated-mainly for fear of medication risk. No terminations due to abnormal prenatal ultrasound findings were reported. Spontaneous abortions occurred in five pregnancies. Of 18 live births including 1 pair of twins 1 major birth defect (small ventricular septal defect) was observed. None of the infants showed symptoms of retinoid embryopathy. 70% (48/69) of the patients with data on contraception did not use any method, in 30% contraception failed. There was no evidence that poor maternal education was a major cause for the omission of contraception documented in 48 women.
CONCLUSION: Inadvertent isotretinoin exposure during the first 2 weeks post conception does not necessarily require discussion of termination of pregnancy, as the risk of major birth defects appears to be much lower than it becomes beyond this period. Nevertheless, additional efforts are required to improve the effectiveness of contraception while on isotretinoin treatment considering psycho-social aspects such as improved self-confidence, unexpected new partnership and sexual activity and incorrect perception of infertility.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19444462     DOI: 10.1007/s00404-009-1112-2

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  13 in total

1.  Implementation of the harmonized EU isotretinoin Pregnancy Prevention Programme: a questionnaire survey among European regulatory agencies.

Authors:  Ineke Crijns; Sabine Straus; Michiel Luteijn; Christine Gispen-de Wied; June Raine; Lolkje de Jong-van den Berg
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

2.  To dispense or not to dispense? Ethical case decision-making in pharmacy practice.

Authors:  Ineke Bolt; Mariëtte van den Hoven; Lyda Blom; Marcel Bouvy
Journal:  Int J Clin Pharm       Date:  2015-12

3.  Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillance.

Authors:  Sarah C MacDonald; Jacqueline M Cohen; Alice Panchaud; Thomas F McElrath; Krista F Huybrechts; Sonia Hernández-Díaz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-07-22       Impact factor: 2.890

4.  Drug safety in pregnancy: the German Embryotox institute.

Authors:  Katarina Dathe; Christof Schaefer
Journal:  Eur J Clin Pharmacol       Date:  2017-10-24       Impact factor: 2.953

5.  The rates of major malformations after gestational exposure to isotretinoin: a systematic review and meta-analysis.

Authors:  Eun Jeong Choi; NaeRy Kim; Ho-Seok Kwak; Hae Ji Han; Kyoung-Chul Chun; Young-Ah Kim; Jae-Whoan Koh; Jung Yeol Han; Sung Hong Joo; Ji Sung Lee; Gideon Koren
Journal:  Obstet Gynecol Sci       Date:  2021-03-17

6.  Isotretinoin exposure during pregnancy: a population-based study in The Netherlands.

Authors:  Ingeborg M Zomerdijk; Rikje Ruiter; Leanne M A Houweling; Ron M C Herings; Miriam C J M Sturkenboom; Sabine M J M Straus; Bruno H Stricker
Journal:  BMJ Open       Date:  2014-11-12       Impact factor: 2.692

Review 7.  Investigation of 7-dehydrocholesterol reductase pathway to elucidate off-target prenatal effects of pharmaceuticals: a systematic review.

Authors:  M R Boland; N P Tatonetti
Journal:  Pharmacogenomics J       Date:  2016-07-12       Impact factor: 3.550

8.  Oral isotretinoin for acne.

Authors:  Caroline S Costa; Ediléia Bagatin; Ana Luiza C Martimbianco; Edina Mk da Silva; Marília M Lúcio; Parker Magin; Rachel Riera
Journal:  Cochrane Database Syst Rev       Date:  2018-11-24

9.  Assessing the availability of the teratogenic drug isotretinoin outside the pregnancy prevention programme: a survey of e-pharmacies.

Authors:  Briege M Lagan; Helen Dolk; Bronagh White; Donald R A Uges; M Sinclair
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-02-03       Impact factor: 2.890

Review 10.  Drug safety: The concept, inception and its importance in patients' health.

Authors:  Thamir M Alshammari
Journal:  Saudi Pharm J       Date:  2014-05-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.